353 related articles for article (PubMed ID: 19344392)
1. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
Teachey DT; Grupp SA; Brown VI
Br J Haematol; 2009 Jun; 145(5):569-80. PubMed ID: 19344392
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
3. m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T; Ferreri AJM
Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
[TBL] [Abstract][Full Text] [Related]
4. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
5. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
Witzig TE; Kaufmann SH
Curr Treat Options Oncol; 2006 Jul; 7(4):285-94. PubMed ID: 16916489
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin as a therapeutic target in leukemia.
Giles FJ; Albitar M
Curr Mol Med; 2005 Nov; 5(7):653-61. PubMed ID: 16305491
[TBL] [Abstract][Full Text] [Related]
8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
9. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Mohindra NA; Platanias LC
Leuk Lymphoma; 2015; 56(9):2518-23. PubMed ID: 25747970
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors in the treatment of cancer.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
[TBL] [Abstract][Full Text] [Related]
11. mTOR signaling and drug development in cancer.
Dancey J
Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
[TBL] [Abstract][Full Text] [Related]
12. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of mTOR inhibitors: a focus on lymphoma.
Smith SM
Rev Recent Clin Trials; 2007 May; 2(2):103-10. PubMed ID: 18473994
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the mammalian target of rapamycin.
Dancey JE
Expert Opin Investig Drugs; 2005 Mar; 14(3):313-28. PubMed ID: 15833062
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
16. PI3K as a target for therapy in haematological malignancies.
Khwaja A
Curr Top Microbiol Immunol; 2010; 347():169-88. PubMed ID: 20517718
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targets: MTOR and related pathways.
Dancey JE
Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
[TBL] [Abstract][Full Text] [Related]
18. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
19. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
20. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
